<DOC>
	<DOCNO>NCT02518698</DOCNO>
	<brief_summary>The goal study provide detail description treatment CRPC ( Castrate Resistant Prostate Cancer ) patient bone metastasis resource utilization cost associate diagnosis subsequent treatment .</brief_summary>
	<brief_title>Treatment Patterns Castrate Resistant Prostate Cancer Patients With Bone Metastases Medicare Population</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>First diagnosis bone metastases member diagnosed prostate cancer find claim data identification period Members age ≥ 65 year index Medicare member medical pharmacy coverage ; Continuously enrol pre postindex period . Member diagnosis cancer ( exclude melanoma ( ICD9 172.x ) metastasis ( ICD9 198.x ) ) index date ; Members age ≥ 89 year age index date</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Castrated resistant prostate cancer</keyword>
	<keyword>Patients bone metastasis</keyword>
</DOC>